Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.77 |
| ▸ | KDR | P35968 | 4/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.74 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.74 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903327 | 1.00 | EGFR (0.77) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL14123493 | 0.92 | EGFR (0.80) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4905713 | 0.87 | EGFR (1.00) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4905720 | 0.87 | EGFR (1.00) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4900529 | 0.87 | HDAC3 (0.75) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL14066930 | 0.87 | HDAC3 (0.78) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4902290 | 0.86 | EGFR (0.76) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4891736 | 0.86 | KDR (0.84) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4902303 | 0.86 | EGFR (0.76) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4900547 | 0.86 | HDAC3 (0.82) | EGFRKDRERBB2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | EGFR 2358/4885KDR 2667/4885ERBB2 2794/4885 |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC1, HDAC2, BAZ2A | EGFR 1171/4885KDR 1887/4885ERBB2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.